A growing number of preclinical and clinical trials have confirmed that traditional cancer therapies can promote the release of tumor-associated antigens (TAAs), increase antigen presentation, as well as enhance the expression of PD-1/PD-L1 axis. This evidence concerns the gene PDCD1 and cancer.